• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 52
  • 35
  • 10
  • 5
  • 3
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • Tagged with
  • 114
  • 114
  • 25
  • 24
  • 18
  • 15
  • 13
  • 12
  • 12
  • 11
  • 10
  • 10
  • 9
  • 9
  • 8
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
21

The functional role of microRNA-433-Azin1 axis in renal fibrosis.

January 2014 (has links)
以客觀存在之腎臟損害和功能異常的臨床表現為診斷依據的腎臟疾病,業已成為全世界所共同面臨的危害人類健康的一項主要健康問題。現今,人群中有超過十分之一的人患有慢性腎臟疾病(CKD), 該病的患病率不亞於糖尿病 (James et al., 2010)。慢性腎髒病是一種難以治癒的疾病。儘管存在有效的治療方法,但在全世界範圍內,慢性腎髒病仍舊是導致終末期腎臟疾病和死亡的首要原因。據2010年全球疾病負擔的研究報導 (Lozano et al., 2013),在引起全球死亡總數原因列表中,慢性腎髒病由1990年的第27位(年齡標準化的每100 000人的年死亡率為15.7)躍升至2010年的第18位(每100 000人的年死亡率為16.3)。慢性腎髒病的攀升趨勢僅次於HIV和AIDS。這種狀況已經引起高度關注,應對措施的實施刻不容緩!因此,迫切需要慢性腎髒病早期診斷和治療的有效方案。 / 纖維化是慢性腎髒病這一以終末期腎髒病(ESRD)為結局的疾病腎臟損傷和進展的主要病理特徵。現已確立转化生长因子β/Smads 信号蛋白(TGF-β/Smad)在腎臟纖維化發病機制中具有主要的作用。在過去近20年對於转化生长因子β/Smads 信号蛋白在慢性腎髒病發病機制中的作用研究揭示:Smad3在腎臟纖維化中起致病作用,而Smad2和Smad7具保護作用。鑒於转化生长因子β/Smads 信号蛋白在免疫調節中也發揮關鍵作用,直接針對转化生长因子β/Smads 信号蛋白的干預方案可能引起免疫損傷的副作用。因而,針對转化生长因子β/Smads 信号蛋白特異性下游靶目標的療法是對抗慢性腎髒病更好的選擇。 / 自首個微小核糖核酸的發現至今,已歷經20年。微小核糖核酸在基因表达的转录后起著重要調節作用。現已明確,在人類疾病包括腎臟病的發生和/或進展中存在微小核糖核酸的表達或功能的失調。最近的研究明確的表明,微小核糖核酸與腎臟疾病的發病機制密切相關。另外,已有確鑿的證據顯示,一些微小核糖核酸正是转化生长因子β/Smads信号蛋白的特異性下游。並且我們發現,不僅在转化生长因子β和血管緊張素II誘導的體外纖維化反應中,而且在小鼠體內梗阻性和高血壓性腎病模型中,微小核糖核酸-433-Azin1軸不但在腎臟纖維化中起重要作用,並且和转化生长因子β/Smad3信号蛋白密切相關。據重要意義的是,藉助安全、有效的超聲微泡介導的基因轉染方法,通過逆轉失調的微小核糖核酸-433-Azin1軸,有效的抑制了小鼠腎臟疾病的進展、腎組織的損傷并減少了蛋白尿的排泄。因此,微小核糖核酸-433-Azin1軸不但可以作為慢性腎臟病早期診斷的生物學標記,也能夠成為遏制甚至逆轉慢性腎髒病的治療靶點。 / 近年來,從基礎到臨床旨在預防和治療慢性腎髒病的研究已取得碩果累累。基於以转化生长因子β/Smad3信号蛋白特異性微小核糖核酸為把目標的治療策略,預見了遏制慢性腎髒病治療的未來希望。然而, 消除慢性腎髒病這一世界性的人類健康威脅,仍需付諸長期不懈的努力。 / Kidney disease is diagnosed with objective clinic manifestation of kidney damage and renal dysfunction has been recognized as a major global health burden. Nowadays, more than one out of ten people have chronic kidney disease (CKD) and the overall prevalence is not less than that of diabetes (James et al., 2010). CKD is a kind of persistent ailment. In spite of the availability of medical treatments, CKD continues to be a leading cause of end stage of renal disease (ESRD) and death worldwide. Reported in the 2010 Global Burden of Disease study (Lozano et al., 2013), CKD was ranked from 27th in 1990 (age-standardised annual death rate of 15.7 per 100 000) and rose to 18th in 2010 (annual death rate 16.3 per 100 000) in the list of causes of total number of global deaths. The growing momentum of CKD was just second to that for HIV and AIDS. This situation has claimed our serious attention and the prompt action is imperative. Thus, effective early diagnosis biomarker and treatment of CKD are urgent needed. / Fibrosis is the key feature during renal lesion formation and progression in CKD which will be ended in ESRD eventually. It has been established that Transforming growth factor β/Combination of the Drosophila protein "Mothers against decapentaplegic" (MAD) and C. elegant protein SMA (TGF-β/Smad) signaling plays a central role in the pathogenesis of renal fibrosis. For last two decades, dissection of the critical role of TGF-β/Smad signaling in the fibrogenesis of CKD has unveiled that Smad3 plays a pathogenic but Smad2 and Smad7 play a protective role in renal fibrosis. As TGF-β/Smad signaling also plays a crucial function in immunity, targeting TGF-β/Smad signaling may cause adverse effect. Thus, targeting specific downstream of T GF-β/Smad signaling should be a better alternative to fight against CKD. / A score of years has elapsed from the first microRNA discovery. MicroRNAs are important post-transcriptional regulators of gene expression. It is now widely acknowledged that the dysregulation of microRNA expression or action underlies the onset and/or development of various human diseases including kidney disease. Recently, researches have substantial evidences that microRNAs are tightly associated with the pathogenesis of kidney disease. In addition, eye-catching tangible evidences showed that several microRNAs are specific downstream of TGF-β/Smad3 signaling. Moreover, we found that not only in TGF-β and angiotensin II induced fibrotic response in vitro, but also in mouse models of obstructive and hypertensive nephropathy, microRNA-433-Azin1 axis is vital in renal fibrosis and is closely related with TGF-β/Smad3 signaling. Last but not least, our study suggests that, using a safe, effective, ultrasound microbubble-mediated gene transfer therapeutic method can significantly halt the progression of kidney lesions and reduce renal tissue damage and the excretion of albuminuria by balancing the microRNA-433-Azin1 axis. Hence, microRNA-433-Azin1 axis may act either as biomarkers favorable early diagnosis or therapeutic targets to halt or even reverse CKD. / The bench and bedside research on preventing and managing CKD have gained fruitful results in recent decades. Therapeutic strategy against TGF-β/Smad3 specific microRNA brings us a bright future in combating against CKD. However, more endeavors are necessary to eliminate the enormous burden of CKD worldwide. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Li, Rong. / Thesis (Ph.D.) Chinese University of Hong Kong, 2014. / Includes bibliographical references (leaves 182-202). / Abstracts also in Chinese.
22

Percutaneous Renal Artery Revascularization in Patients with Atherosclerotic Renal Artery Stenosis and Chronic Kidney Disease

Dichtel, Laura Elisabeth 11 September 2009 (has links)
The impact of percutaneous renal artery angioplasty and stenting (PTRAS) for treatment of atherosclerotic renal artery stenosis (ARAS) is not fully understood, especially in patients with chronic kidney disease (CKD). We performed a retrospective cohort study of patients with significant ARAS and moderate to severe chronic kidney disease (estimated GFR 15-60 ml/min/1.73m2) who were treated medically or with PTRAS. The primary endpoint of this study was change in renal function over the first year after treatment. Secondary endpoints included hemodynamic outcomes, antihypertensive medication doses, end stage renal disease (ESRD), and death. We reviewed all patients with a diagnosis of significant ARAS and impaired GFR treated between 1997-2007 in the Veterans Affairs Connecticut Healthcare System (VACHS). A total of 118 patients met inclusion criteria (71 medical treatment, 47 PTRAS), with an average follow-up of 34 months. The students t-test was used to compare baseline characteristics, as well as renal and hemodynamic endpoints between the two treatment groups. The cohort had a mean age of 73 ± 9 years and average baseline GFR of 37.2 ± 14.9 ml/min/1.73m2. Demographic, clinical and laboratory characteristics at baseline were similar between the two groups, with the exception of higher diastolic blood pressure in the stent group at baseline (75 versus 70 mmHg, p=0.028). No statistically significant difference was found between the two treatment groups for any renal endpoints. After a steady decline in GFR in both the medical treatment and stent groups during the 12 months preceding diagnosis (-4.2 versus -4.0 ml/min/1.73m2, p=0.911), GFR stabilized in both groups over the year following diagnosis (decline in GFR of -1.6 versus -1.4 ml/min/1.73m2, p=0.938). Multivariate models did not reveal an association between treatment modality and percent change in GFR during follow-up. No difference was found in blood pressure outcomes at 12 months between the medical and stent groups. Antihypertensive therapy, measured in defined daily doses (DDDs), was significantly higher in the medical treatment group at 12 months (4.5 versus 3.5 DDDs, p=0.048), but lost significance thereafter. In addition, the number of deaths was significantly higher in the stented group on univariate analysis, although this did not remain significant on multivariable Cox analysis. No difference was found between treatment groups in the development of ESRD. These data suggest that, among patients with ARAS and CKD, medical therapy and renal artery stenting are comparable in stabilizing renal function.
23

Clinical significance of chronic kidney disease in the elderly

Daniel, Kathryn Marie. January 2008 (has links)
Thesis (Ph.D.) -- University of Texas at Arlington, 2008.
24

Predicting the development of azotaemia in geriatric cats

Finch, Natalie Clare January 2011 (has links)
No description available.
25

Mechanisms of fibrosis in feline chronic kidney disease

Chakrabarti, Shubro January 2012 (has links)
No description available.
26

Is hyperthyroidism damaging to the feline kidney?

Williams, Timothy Lee January 2013 (has links)
No description available.
27

Genetic dissection of hypertension-related renal disease using the Dahl salt-sensitive rat

Garrett, Michael R. January 2006 (has links)
Dissertation (Ph.D.)--University of Toledo, 2006. / "In partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biomedical Sciences." Title from title page of PDF document. Bibliography: p. 89-95, p. 127-131, p. 184-192, p.198-233.
28

Renal function after transplantation of the liver and intestine /

Herlenius, Gustaf, January 2010 (has links)
Diss. (sammanfattning) Göteborg : Göteborgs universtiet, 2010. / Härtill 4 uppsatser.
29

Women's perceptions of factors that enhance and inhibit adaptation to chronic hemodialysis when renal transplantation is not an option

Maxwell, Lynne January 1990 (has links)
Factors Influencing Women's Adaptation to Hemodialysis When Renal Transplantation is not an Option The intent of this study was to explore and describe factors that influence adaptation from the perspective of women on hemodialysis for whom renal transplantation is not an option. Phenomenology was the research design selected for this study in order to understand the experience of these women clients. Data were collected during audio-taped interviews of eight women and were analyzed concurrently with data collection to identify common themes. Two central themes emerged: the adaptation process and the theme of connectedness. The adaptation process was described as a six-phase process. Connectedness was defined as being connected to others and/or sources of life's energy. Several key factors that either facilitated or interfered with adaptation were identified for each of these two themes. Key factors that facilitated adaptation throughout the adaptation process Included a first run on dialysis, experience with adversity, emotional and instrumental support, coping behaviors such as asserting control and reframing the situation, diversions, adequate rest and confidence in health-care professionals. Factors interfering with adaptation to hemodialysis throughout the adaptation process included the gradual and ambiguous nature of renal disease, increasing dependence, reduced energy, transportation to dialysis, compromised somatic health, difficulty with assertiveness, prolonged stressors and lack of confidence in health-care professionals. Specific factors that influenced connectedness were identified. The facilitating factors identified were satisfactory relationships, nurturing others, normalizing, a harmonious atmosphere on the hemodialysis unit and pleasurable activities. Key factors interfering with adaptation related to the connectedness theme were isolation from others, unsympathetic others, ineffective communication with health-care professionals, and exclusion from activities. The findings relative to the adaptation process were discussed in the light of the literature on adapting to illness and stress. Connectedness was discussed primarily in relation to the literature exploring the socialization of women. Implications for nursing practice, education and research arising from these findings were outlined. / Applied Science, Faculty of / Nursing, School of / Graduate
30

The occurance of genetic variations in the MYH9 gene and their association with CKD in a mixed South African population

Masconi, Katya 12 1900 (has links)
Thesis (MScMedSc)--Stellenbosch University, 2012. / ENGLISH ABSTRACT: The purpose of this study was to investigate the association of the selected MYH9 single nucleotide polymorphisms (SNPs) with chronic kidney disease (CKD) and its related co-morbidities in the South African mixed ancestry population residing in Bellville South, Cape Town. In 2008, two landmark studies identified SNPs in the MYH9 gene which explained most of the increased risk for non-diabetic CKD in African Americans. These polymorphisms were later found to be weakly associated with diabetic nephropathy. Three SNPs that exhibited independent evidence for association with CKD were selected (rs5756152, rs4821480 and rs12107). These were genotyped using a Taqman genotyping assay on a BioRad MiniOpticon and confirmed by sequencing in 724 subjects from Bellville South, Cape Town, South Africa. Prevalent CKD was defined based on the estimated glomerular filtration rate calculated using the modification of diet in renal disease (MDRD) formula. Chronic kidney disease was present in 214 subjects (29.6%), 96.3% were stage 3 and only 8 subjects were stage 4. In additive allelic models, adjusted for age and gender, rs5756152 demonstrated an association with kidney function whereby each G allele of rs5756152 increased eGFR by 3.67 ml/min/1.73, reduced serum creatinine by 4.5% and increased fasting plasma glucose by 0.51 mmol/L. When an interaction model was used, the effect of rs5756152 on serum creatinine, eGFR and blood glucose levels was retained, and enhanced, but only in diabetic subjects. In addition, rs4821480 T allele increased eGFR while rs12107 A allele decreased glucose levels in diabetic subjects. In contrast to reports that MYH9 SNPs are strongly associated with non-diabetic end stage renal disease, our study demonstrated that rs5756152 and rs4821480 are associated with early kidney function derangements in type 2 diabetes whilst rs12107 is associated with glucose metabolism. Our findings, along with previous reports, suggest that the MYH9 gene may have a broader genetic risk effect on different types of kidney diseases than previously thought. / AFRIKAANSE OPSOMMING: Hierdie studie het ondersoek ingestel na die verband tussen drie gekose MYH9-enkelnukleotied-polimorfismes (SNP’s) en chroniese niersiekte (hierna ‘niersiekte’), wat verwante ko-morbiditeite insluit, onder ’n Suid-Afrikaanse populasie van gemengde afkoms in Bellville-Suid, Kaapstad. Twee rigpuntstudies het in 2008 op SNP’s in die MYH9-geen afgekom wat verklaar het waarom Afro-Amerikaners ’n hoër risiko vir niediabetiese niersiekte toon. Later is bevind dat hierdie polimorfismes ook ’n swak verband met diabetiese nefropatie het. Drie SNP’s wat elk onafhanklik bewys gelewer het van ’n verband met niersiekte is vervolgens gekies (rs5756152, rs4821480 en rs12107). Die SNP’s is daarná met behulp van die Taqman-toets op ’n BioRad MiniOpticon aan genotipering onderwerp, en is toe deur middel van reeksbepaling by 724 proefpersone van Bellville-Suid, Kaapstad, Suid-Afrika, bevestig. Die voorkoms van niersiekte is bepaal op grond van die geraamde glomerulêre filtrasietempo (eGFR), wat aan die hand van die ‘niersiekte-dieetveranderings’- (MDRD-)formule bereken is. Daar is bevind dat 214 proefpersone (29,6%) aan chroniese niersiekte ly – 96,3% was in fase 3 en slegs agt proefpersone in fase 4. In toegevoegde alleliese modelle wat vir ouderdom en geslag aangepas is, het rs5756152 ’n verband met nierfunksie getoon: Elke G-allel van rs5756152 het eGFR met 3,67 ml/min/1,73 verhoog, serumkreatinien met 4,5% verlaag en vastende plasmaglukose met 0,51 mmol/L verhoog. Toe ’n interaksiemodel gebruik is, is die effek van rs5756152 op serumkreatinien, eGFR en bloedglukosevlakke behou en versterk, hoewel slegs by diabetiese proefpersone. Daarbenewens het die T-allel van rs4821480 eGFR verhoog, terwyl die A-allel van rs12107 ook glukosevlakke by diabetiese proefpersone verlaag het. In teenstelling met bewerings dat MYH9-SNP’s ’n sterk verband met niediabetiese eindstadiumniersiekte toon, het hierdie studie bewys dat rs5756152 en rs4821480 met vroeë nierfunksieversteurings by tipe 2-diabetes verband hou, terwyl rs12107 weer met glukosemetabolisme verbind word. Tesame met vorige studies, doen hierdie navorsingsbevindinge dus aan die hand dat die MYH9-geen dalk ’n groter genetiese risiko-effek op verskillende tipes niersiekte het as wat voorheen vermoed is. / Cape Peninsula University of Technology Research Fund / University of Stellenbosch Merit Bursary

Page generated in 0.0737 seconds